Merck (MRK) Intangibles (2009 - 2026)
Merck (MRK) posted quarterly Intangibles of $25.7 billion for Q1 2026, up 63.38% YoY from $15.8 billion in Q1 2025, and down 3.51% sequentially from $26.7 billion in Q4 2025.
Merck (MRK) Intangibles (2009 - 2026) Analysis & Trends
Merck has disclosed Intangibles across 18 years of filings, most recently posting $25.7 billion for Q1 2026.
- In Q1 2026, Intangibles rose 63.38% year-over-year to $25.7 billion; the TTM figure through Mar 2026 stood at $25.7 billion (up 63.38% YoY), while the FY2025 annual figure was $26.7 billion, up 62.99% from the prior year.
- Intangibles fell to $25.7 billion in Q1 2026, from $26.7 billion in the prior quarter.
- Over the last five years, Intangibles for MRK reached as high as $26.7 billion in Q4 2025 and fell as low as $15.2 billion in Q2 2025.
- The 5-year median for Intangibles is $19.2 billion (2023), against an average of $19.4 billion.
- Annual changes were most pronounced in 2022 — Intangibles soared 65.15% — and 2023, when it retreated 13.75%.
- A 5-year view of Intangibles shows it stood at $20.3 billion in 2022, then decreased by 11.14% to $18.0 billion in 2023, then fell by 9.11% to $16.4 billion in 2024, then jumped by 62.99% to $26.7 billion in 2025, then dropped by 3.51% to $25.7 billion in 2026.
- According to Business Quant data, Intangibles over the past three periods registered $25.7 billion, $26.7 billion, and $15.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 7.37 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 49.06 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 50.87 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 36.91 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 25.75 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 21.38 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 16.38 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 52.56 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | 11.30 Bn |
| 10 | Biogen | 30.87 Bn | 26.59 Bn | 1.82 Bn | 9.05 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 25.75 Bn |
| Dec 31, 2025 | 26.68 Bn |
| Sep 30, 2025 | 15.31 Bn |
| Jun 30, 2025 | 15.19 Bn |
| Mar 31, 2025 | 15.76 Bn |
| Dec 31, 2024 | 16.37 Bn |
| Sep 30, 2024 | 17.01 Bn |
| Jun 30, 2024 | 16.98 Bn |
| Mar 31, 2024 | 17.57 Bn |
| Dec 31, 2023 | 18.01 Bn |
| Sep 30, 2023 | 19.20 Bn |
| Jun 30, 2023 | 19.67 Bn |
| Mar 31, 2023 | 19.86 Bn |
| Dec 31, 2022 | 20.27 Bn |
| Sep 30, 2022 | 21.37 Bn |
| Jun 30, 2022 | 22.50 Bn |
| Mar 31, 2022 | 23.02 Bn |
| Dec 31, 2021 | 22.93 Bn |
| Sep 30, 2021 | 13.38 Bn |
| Jun 30, 2021 | 13.62 Bn |